BIOSPECIFICS
TECHNOLOGIES CORP.
|
Delaware
|
0-19879
|
11-3054851
|
(State
or Other Jurisdiction
|
(Commission
File Number)
|
(I.R.S.
Employer
|
Of
Incorporation)
|
Identification
No.)
|
|
Item
No.
|
Page
|
|
|
PART II | |
Item 7.
FINANCIAL STATEMENTS
|
1
|
|
|
PART IV
|
|
Item 15.
EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
|
22
|
|
2
|
|
|
|
3
|
|
4
|
|
5
|
|
6
|
|
8
|
|
Years
ended December 31,
|
||||||||||||
2005
|
2004
|
2003
|
||||||||||
Assets
|
||||||||||||
Current
assets:
|
||||||||||||
Cash
and cash equivalents
|
$ | 539,380 | $ | 1,345,800 | $ | 268,998 | ||||||
Marketable
securities
|
- | 3,026 | 3,026 | |||||||||
Accounts
receivable, net
|
445,141 | 160,777 | 306,786 | |||||||||
Inventories,
net
|
2,616,716 | 2,005,263 | 880,452 | |||||||||
Prepaid
expenses and other current assets
|
129,234 | 109,041 | 108,540 | |||||||||
Total
current assets
|
3,730,471 | 3,623,907 | 1,567,802 | |||||||||
Other
assets – loan costs
|
- | 54,817 | 193,707 | |||||||||
Construction
in Progress
|
59,106 | - | - | |||||||||
Property,
plant and equipment, net
|
2,795,355 | 3,395,391 | 3,845,103 | |||||||||
Total
assets
|
6,584,932 | 7,074,115 | 5,606,612 | |||||||||
Liabilities
and Stockholders' Equity
|
||||||||||||
Current
liabilities:
|
||||||||||||
Accounts
payable and accrued expenses
|
2,638,832 | 2,494,168 | 2,048,812 | |||||||||
Deferred
revenue
|
2,137,517 | 985,755 | 45,000 | |||||||||
Deferred
employee stock bonus plan
|
168,900 | - | - | |||||||||
Notes
payable to related parties
|
69,894 | 67,839 | 20,953 | |||||||||
Short-term
debt - Korpodeko
|
- | 182,000 | 364,000 | |||||||||
Short-term
debt - promissory note
|
- | 100,000 | 100,000 | |||||||||
Total
current liabilities
|
5,015,143 | 3,829,762 | 2,578,765 | |||||||||
Deferred
revenue - license fees
|
4,753,797 | 3,672,200 | - | |||||||||
Minority
interest in subsidiaries
|
(2,064 | ) | 5,345 | 83,354 | ||||||||
Deferred
Compensation
|
22,210 | 22,210 | - | |||||||||
Senior
secured convertible 12% note, net of discount
|
- | 1,504,863 | 1,364,591 | |||||||||
Stockholders'
equity:
|
||||||||||||
Series
A Preferred stock, $.50 par value, 700,000 shares authorized; none
outstanding
|
- | - | - | |||||||||
Common
stock, $.001 par value; 10,000,000 shares authorized; 5,362,716,
5,333,841 and 5,249,528 shares issued and outstanding at
December 31, 2005, 2004 and 2003 respectively
|
5,363 | 5,334 | 5,250 | |||||||||
Additional
paid-in capital
|
4,224,964 | 4,250,509 | 4,144,207 | |||||||||
Retained
earnings
|
(4,877,590 | ) | (3,580,844 | ) | 77,897 | |||||||
Treasury
stock, 346,561 shares at cost as of December 31, 2005 and 361,380 shares
at cost as of December 31, 2004 and 2003
|
(1,832,864 | ) | (1,911,237 | ) | (1,911,237 | ) | ||||||
Notes
receivable from former Chairman and CEO and other
related party
|
(724,027 | ) | (724,027 | ) | (736,215 | ) | ||||||
Total
stockholders' equity
|
(3,204,154 | ) | (1,960,265 | ) | 1,579,902 | |||||||
Total liabilities and
stockholders’ equity
|
$ | 6,584,932 | $ | 7,074,115 | $ | 5,606,612 | ||||||
See
accompanying notes to consolidated financial statements
|
Twelve
months ended December 31,
|
||||||||||||
2005
|
2004
|
2003
|
||||||||||
Revenues:
|
||||||||||||
Net
sales
|
$ | 3,137,978 | $ | 1,664,779 | $ | 1,555,625 | ||||||
Licensing
fees
|
1,266,641 | 387,045 | - | |||||||||
Royalties
|
1,073,620 | 784,933 | 1,683,915 | |||||||||
5,478,239 | 2,836,757 | 3,239,540 | ||||||||||
Costs
and expenses:
|
||||||||||||
Cost
of sales
|
3,622,775 | 3,052,492 | 2,837,986 | |||||||||
Research
and development
|
686,464 | 1,057,009 | 935,443 | |||||||||
General
and administrative
|
2,289,160 | 2,094,424 | 2,632,399 | |||||||||
6,598,399 | 6,203,925 | 6,405,828 | ||||||||||
Operating
loss
|
(1,120,160 | ) | (3,367,168 | ) | (3,166,288 | ) | ||||||
Other
income (expense):
|
||||||||||||
Investment
income
|
2,406 | 196 | 109,635 | |||||||||
Interest
expense
|
(177,764 | ) | (369,778 | ) | (213,677 | ) | ||||||
Other
expense
|
(2,519 | ) | - | - | ||||||||
(177,877 | ) | (369,582 | ) | (104,042 | ) | |||||||
Loss
before benefit (expense) for income tax
|
(1,298,037 | ) | (3,736,750 | ) | (3,270,330 | ) | ||||||
Income
tax benefit (expense)
|
(6,118 | ) | - | (13,000 | ) | |||||||
(1,304,155 | ) | (3,736,750 | ) | (3,283,330 | ) | |||||||
Loss
before minority interest
|
(1,304,155 | ) | (3,736,750 | ) | (3,283,330 | ) | ||||||
Minority
interest in loss of consolidated subsidiaries
|
7,409 | 78,009 | 83,787 | |||||||||
Net
loss
|
$ | (1,296,746 | ) | $ | (3,658,741 | ) | $ | (3,199,543 | ) | |||
Basic
and diluted net loss per share
|
$ | (0.26 | ) | $ | (0.75 | ) | $ | (0.68 | ) | |||
Shares
used in computation of basic and diluted net loss per
share
|
4,989,538 | 4,903,773 | 4,734,867 | |||||||||
See
accompanying notes to consolidated financial statements
|
Twelve
months ended December 31,
|
||||||||||||
Cash
flows from operating activities:
|
2005
|
2004
|
2003
|
|||||||||
Net
loss
|
$ | (1,296,746 | ) | $ | (3,658,741 | ) | $ | (3,199,543 | ) | |||
Adjustments
to reconcile net loss to net cash provided
|
||||||||||||
by
operating activities:
|
||||||||||||
Depreciation
and amortization
|
653,209 | 644,359 | 699,129 | |||||||||
Options
and warrants issued for services
|
- | - | 14,000 | |||||||||
Issuance
of stock for services
|
16,125 | 40,960 | 15,000 | |||||||||
Issuance
of treasury stock as employee bonus
|
22,969 | - | - | |||||||||
Amortization
of loan discount
|
70,137 | 140,272 | 70,137 | |||||||||
Deferred
compensation
|
- | 22,210 | - | |||||||||
Minority
interest in loss of subsidiaries
|
(7,409 | ) | (78,009 | ) | (83,787 | ) | ||||||
Changes
in operating assets and liabilities:
|
||||||||||||
Accounts
receivable
|
(284,364 | ) | 146,009 | 562,024 | ||||||||
Marketable
securities
|
3,026 | - | - | |||||||||
Inventories
|
(611,453 | ) | (1,124,811 | ) | (231,572 | ) | ||||||
Prepaid
expenses and other current assets
|
(20,194 | ) | (501 | ) | (74,392 | ) | ||||||
Accounts
payable and accrued expenses
|
144,644 | 445,356 | 264,156 | |||||||||
Deferred
revenue
|
2,233,359 | 4,612,955 | - | |||||||||
Deferred
employee stock bonus plan
|
168,900 | - | - | |||||||||
Income
taxes
|
- | - | 417,000 | |||||||||
Net
cash provided by (used in) operating activities
|
1,092,223 | 1,190,059 | (1,547,848 | ) | ||||||||
Cash
flows from investing activities:
|
||||||||||||
Net
(increase) decrease of notes receivable from former Chairman and
CEO
|
- | 12,189 | 394,093 | |||||||||
Expenditures
for property, plant and equipment
|
(112,279 | ) | (194,647 | ) | (16,189 | ) | ||||||
Net
cash provided by (used in) investing activities
|
(112,279 | ) | (182,458 | ) | 377,904 | |||||||
Cash
flows from financing activities:
|
||||||||||||
Interest
accrued on notes payable to related parties
|
2,055 | 1,886 | 6,443 | |||||||||
Increase
in short-term debt
|
- | 45,000 | 100,000 | |||||||||
Decrease
in short-term debt
|
(282,000 | ) | (182,000 | ) | (91,000 | ) | ||||||
Increase
(decrease) in senior secured convertible debt
|
(1,575,000 | ) | - | 1,575,000 | ||||||||
Proceeds
from issuance of common stock
|
13,763 | 65,425 | 295 | |||||||||
Deferred
loan costs, net
|
54,817 | 138,890 | (193,707 | ) | ||||||||
Net
cash provided by (used in) financing activities
|
(1,786,365 | ) | 69,201 | 1,397,031 | ||||||||
Effect
of exchange rates on cash and equivalents
|
- | - | (8,988 | ) | ||||||||
Increase
(decrease) in cash and cash equivalents
|
(806,420 | ) | 1,076,802 | 218,099 | ||||||||
Cash
and cash equivalents at beginning of year
|
1,345,800 | 268,998 | 50,899 | |||||||||
Cash
and cash equivalents at end of year
|
539,380 | 1,345,800 | 268,998 | |||||||||
Supplemental
disclosures of cash flow information:
|
||||||||||||
Cash
paid during the year for:
|
||||||||||||
Interest
|
$ | - | $ | 211,568 | $ | 157,599 | ||||||
See
accompanying notes to consolidated financial
statements
|
Shares
|
Amount
|
Additional
Paid in Capital
|
Retained
Earnings
|
|||||||||||||||||
Balances
- December 31, 2002
|
4,939,216 | $ | 4,939 | $ | 3,834,677 | $ | 3,277,440 | |||||||||||||
Foreign
currency translation
|
- | - | - | - | ||||||||||||||||
Consultant
option grants
|
15,000 | 15 | 14,985 | - | ||||||||||||||||
Bio
Partners loan/discount
|
295,312 | 296 | 280,545 | - | ||||||||||||||||
Issuance
of warrants, options
|
- | - | 14,000 | - | ||||||||||||||||
Proceeds
from former Chairman and CEO
|
- | - | - | - | ||||||||||||||||
Net
loss
|
- | - | - | (3,199,543 | ) | |||||||||||||||
Balances
- December 31, 2003
|
5,249,528 | $ | 5,250 | $ | 4,144,207 | $ | 77,897 | |||||||||||||
Shares
for services
|
18,888 | 19 | 40,941 | - | ||||||||||||||||
Exercise
of options
|
65,425 | 65 | 65,360 | - | ||||||||||||||||
Proceeds
from former Chairman and CEO
|
- | - | - | - | ||||||||||||||||
Net
loss
|
- | - | - | (3,658,741 | ) | |||||||||||||||
Balances
- December 31, 2004
|
5,333,841 | $ | 5,334 | $ | 4,250,508 | $ | (3,580,844 | ) | ||||||||||||
Shares
for services
|
15,000 | 15 | 16,110 | - | ||||||||||||||||
Exercise
of options
|
13,875 | 14 | 13,749 | - | ||||||||||||||||
Proceeds
from former Chairman and CEO
|
- | - | - | - | ||||||||||||||||
Issue
of treasury shares
|
- | - | (55,404 | ) | - | |||||||||||||||
Net
loss
|
- | - | - | (1,296,746 | ) | |||||||||||||||
Balances
- December 31, 2005
|
5,362,716 | $ | 5,363 | $ | 4,224,963 | $ | (4,877,590 | ) | ||||||||||||
Shareholder
|
||||||||||||||||||||
Treasury
|
Due
from
|
Currency
|
Equity
|
Comprehensive
|
||||||||||||||||
Stock
|
Chairman
|
Translation
|
Total
|
Income
(loss)
|
||||||||||||||||
Balances
- December 31, 2002
|
(1,911,237 | ) | (1,130,308 | ) | 8,988 | 4,084,498 | -- | |||||||||||||
Foreign
currency translation
|
-- | -- | (8,988 | ) | (8,988 | ) | (8,988 | ) | ||||||||||||
Consultant
option grants
|
-- | -- | -- | 15,000 | -- | |||||||||||||||
Bio
Partners loan/discount
|
-- | -- | -- | 280,841 | -- | |||||||||||||||
Issuance
of warrants, options
|
-- | -- | -- | 14,000 | -- | |||||||||||||||
Proceeds
from former Chairman and CEO
|
-- | 394,093 | -- | 394,094 | -- | |||||||||||||||
Net
loss
|
-- | -- | -- | (3,199,543 | ) | (3,199,543 | ) | |||||||||||||
Balances
- December 31, 2003
|
(1,911,237 | ) | $ | (736,215 | ) | $ | - | $ | 1,579,902 | $ | (3,208,531 | ) | ||||||||
Shares
for services
|
- | - | - | 40,960 | - | |||||||||||||||
Exercise
of options
|
- | - | - | 65,425 | - | |||||||||||||||
Proceeds
from former Chairman and CEO
|
- | 12,188 | - | 12,189 | - | |||||||||||||||
Net
loss
|
- | - | - | (3,658,741 | ) | (3,658,741 | ) | |||||||||||||
Balances
- December 31, 2004
|
(1,911,237 | ) | $ | (724,027 | ) | $ | - | $ | (1,960,265 | ) | $ | (6,867,272 | ) | |||||||
Shares
for services
|
- | - | - | 16,125 | - | |||||||||||||||
Exercise
of options
|
- | - | - | 13,763 | - | |||||||||||||||
Proceeds
from former Chairman and CEO
|
- | - | - | -- | - | |||||||||||||||
Issue
of treasury shares
|
78,373 | - | - | 22,969 | - | |||||||||||||||
Net
loss
|
- | - | - | (1,296,746 | ) | (1,296,746 | ) | |||||||||||||
Balances
- December 31, 2005
|
(1,832,864 | ) | $ | (724,027 | ) | $ | - | $ | (3,204,154 | ) | $ | (8,164,018 | ) | |||||||
See
accompanying notes to consolidated financial statements
|
Twelve
Months Ended
|
||||||||||||
December
31, 2003
|
||||||||||||
As
Previously Reported
|
Adjustment
|
As
Restated
|
||||||||||
Assets
|
||||||||||||
Current
assets:
|
||||||||||||
Cash
and cash equivalents
|
$ | 268,998 | $ | - | $ | 268,998 | ||||||
Marketable
securities
|
3,026 | - | 3,026 | |||||||||
Accounts
receivable, net
|
306,786 | - | 306,786 | |||||||||
Inventories,
net
|
880,452 | - | 880,452 | |||||||||
Prepaid
expenses and other current assets
|
47,151 | 61,389 | (1) | 108,540 | ||||||||
Total
current assets
|
1,506,413 | 61,389 | 1,567,802 | |||||||||
Other
assets - loan costs
|
203,457 | (9,750 | ) | (2) | 193,707 | |||||||
Property,
plant and equipment, net
|
3,845,102 | 1 | (3) | 3,845,103 | ||||||||
Total
assets
|
$ | 5,554,972 | $ | 51,640 | $ | 5,606,612 | ||||||
Liabilities
and Stockholders' Equity
|
||||||||||||
Current
liabilities:
|
||||||||||||
Accounts
payable and accrued expenses
|
$ | 1,806,850 | $ | 241,963 | (4) | $ | 2,048,813 | |||||
Notes
payable to related parties
|
15,010 | 5,943 | (5) | 20,953 | ||||||||
Deferred
revenue
|
45,000 | - | 45,000 | |||||||||
Short-term
debt – Korpodeko
|
364,000 | - | 364,000 | |||||||||
Short-term
debt - promissory note
|
100,000 | - | 100,000 | |||||||||
Total
current liabilities
|
2,330,860 | 247,906 | 2,578,766 | |||||||||
Minority
interest in subsidiaries
|
89,728 | (6,374 | ) | (6) | 83,354 | |||||||
Senior
secured convertible 12% note, net of discount
|
1,364,591 | - | 1,364,591 | |||||||||
Stockholders'
equity:
|
||||||||||||
Series
A Preferred stock, $.50 par value, 700,000 shares
|
||||||||||||
authorized;
none outstanding
|
- | - | - | |||||||||
Common
stock, $.001 par value; 10,000,000 shares
|
||||||||||||
authorized;
5,249,528 shares issued as of December 31, 2003 5,249
|
1 | (7) | 5,250 | |||||||||
Additional
paid-in capital
|
4,144,207 | - | 4,144,207 | |||||||||
Retained
earnings
|
180,949 | (103,052 | ) | (8) | 77,897 | |||||||
Accumulated
other comprehensive income
|
- | - | - | |||||||||
Treasury
stock, 361,380 shares at cost
|
(1,911,237 | ) | - | (1,911,237 | ) | |||||||
Notes
receivable from former Chairman and CEO and other related
party
|
(649,375 | ) | (86,841 | ) | (9) | (736,215 | ) | |||||
Total
stockholders' equity
|
1,769,793 | (189,891 | ) | 1,579,901 | ||||||||
Total
liabilities and stockholders’ equity
|
$ | 5,554,972 | $ | 51,640 | $ | 5,606,612 | ||||||
See
accompanying notes to consolidated financial statements
|
(1)
Correction to prepaid insurance of $31,079 and prepaid payroll of
$30,310 previously expensed.
|
(2)
Correction to Bio Partners, a private investor group, loan
amortization of $9,750.
|
(3)
Rounding correction of property, plant and equipment,
net.
|
(4)
Increase in rent accrual for Lynbrook, NY facility of $206,963 for
2003 and prior periods and payroll tax liability for our Curacao employees
of $35,000 resulting in total additional expense of
$241,963.
|
(5) Increase in interest expense owed
to a related party and a former director of
$5,943
|
(6)
Change due to restated financial statements based on ownership
percentage held by minority shareholders.
|
(7)
Correction of rounding error for outstanding
shares.
|
(8)
Correction to retained earnings based on restatement and prior
period adjustments affecting the consolidated statement of
operations.
|
(9)
Correction of related party loan payment received from former
Chairman and CEO, misapplied to principal instead of interest
due.
|
Twelve
Months ended
|
|||||||||||||
December
31, 2003
|
|||||||||||||
As
Previously Reported
|
Adjustment
|
As
Restated
|
|||||||||||
Revenues:
|
|||||||||||||
Net
sales
|
$ | 1,555,625 | $ | - | $ | 1,555,625 | |||||||
Royalties
|
1,683,915 | - | 1,683,915 | ||||||||||
3,239,540 | - | 3,239,540 | |||||||||||
Costs
and expenses:
|
|||||||||||||
Cost
of sales
|
2,843,921 | (5,935 | ) | (1) | 2,837,986 | ||||||||
General
and administrative
|
2,615,007 | 17,392 | (2) | 2,632,399 | |||||||||
Research
and development
|
884,685 | 50,758 | (3) | 935,443 | |||||||||
6,343,613 | 62,215 | 6,405,828 | |||||||||||
Operating
loss
|
(3,104,073 | ) | (62,215 | ) | (3,166,288 | ) | |||||||
Other
income (expense):
|
|||||||||||||
Investment
Income
|
22,794 | 86,841 | (4) | 109,635 | |||||||||
Interest
expense
|
(207,734 | ) | (5,943 | ) | (5) | (213,677 | ) | ||||||
(184,940 | ) | 80,898 | (104,042 | ) | |||||||||
Loss
before benefit (expense) for income tax
|
(3,289,013 | ) | 18,683 | (3,270,330 | ) | ||||||||
Income
tax expense
|
(13,000 | ) | - | (13,000 | ) | ||||||||
Loss
before minority interest
|
(3,302,013 | ) | 18,683 | (3,283,330 | ) | ||||||||
Minority
interest in earnings of consolidated subsidiaries
|
77,413 | 6,374 | (6) | 83,787 | |||||||||
Net
loss
|
$ | (3,224,600 | ) | $ | 25,057 | $ | (3,199,543 | ) | |||||
Basic
and diluted net loss per share
|
$ | (0.68 | ) | $ | 0.00 | $ | (0.68 | ) | |||||
Shares
used in computation of basic and diluted net loss per
share
|
4,734,867 |
NA
|
4,734,867 | ||||||||||
See
accompanying notes to consolidated financial statements
|
(1)
Cost of sales decrease is related to a reduction in
insurance expense of $19,007 and payroll costs of $30,310 partially offset
by increases in payroll tax expense of $35,000 for our Curacao employees
and rent expense of $8,382 resulting in a total reduction of
$5,935.
|
(2)
General and administrative expense increases include $19,714
related to rent expense and $9,750 related to loan amortization costs with
a private investor group, Bio Partners, partially offset by reductions of
$12,072 in insurance expenses resulting in a total increase of
$17,392.
|
(3)
Research and development expense increases include $50,758 related to rent
expense.
|
(4)
Investment income increased by $86,841due to a reclassification of
interest associated with the related party loan repayment by the former
Chairman and CEO.
|
(5) Interest
expense increased by $5,943 due to a correction to a related party loan to
the former Chairman and CEO.
|
(6)
Change due to restated financial statements based on ownership percentage
held by minority shareholders.
|
Twelve
months ended
|
|||||||||||||
December
31, 2003
|
|||||||||||||
As Previously Reported
|
Adjustment
|
As Restated
|
|||||||||||
Cash
flows from operating activities:
|
|||||||||||||
Net
loss
|
$ | (3,224,600 | ) | $ | 25,057 | (1) | $ | (3,199,543 | ) | ||||
Adjustments
to reconcile net loss to net cash provided
|
|||||||||||||
by
operating activities:
|
|||||||||||||
Depreciation
and amortization
|
699,129 | - | 699,129 | ||||||||||
Options
and warrants issued for services
|
14,000 | - | 14,000 | ||||||||||
Issuance
of stock for services
|
15,000 | - | 15,000 | ||||||||||
Amortization
of loan discount
|
70,137 | - | 70,137 | ||||||||||
Minority
interest in loss of subsidiaries
|
(77,413 | ) | (6,374 | ) | (2) | (83,787 | ) | ||||||
Deferred
taxes
|
- | - | - | ||||||||||
Changes
in operating assets and liabilities:
|
|||||||||||||
Accounts
receivable
|
562,024 | - | 562,024 | ||||||||||
Inventories
|
(231,572 | ) | - | (231,572 | ) | ||||||||
Prepaid
expenses and other current assets
|
(13,003 | ) | (61,389 | ) | (3) | (74,392 | ) | ||||||
Accounts
payable and accrued expenses
|
150,302 | 113,854 | (4) | 264,156 | |||||||||
Income
taxes
|
417,000 | - | 417,000 | ||||||||||
Net
cash provided (used) by operating activities
|
(1,618,996 | ) | 71,148 | (1,547,848 | ) | ||||||||
Cash
flows from investing activities:
|
|||||||||||||
Net
paydown of notes receivable from former Chairman and CEO
|
480,934 | (86,841 | ) | (5) | 394,093 | ||||||||
Expenditures
for property, plant and equipment
|
(16,189 | ) | - | (16,189 | ) | ||||||||
Net
cash provided (used) by investing activities
|
464,745 | (86,841 | ) | 377,904 | |||||||||
Cash
flows from financing activities:
|
|||||||||||||
Interest
accrued on notes payable to related parties
|
500 | 5,943 | (6) | 6,443 | |||||||||
Increase
in short-term debt
|
100,000 | - | 100,000 | ||||||||||
Decrease
in short-term debt
|
(91,000 | ) | - | (91,000 | ) | ||||||||
Proceeds
from senior secured convertible debt
|
1,575,000 | - | 1,575,000 | ||||||||||
Proceeds
from issuance of common stock
|
295 | - | 295 | ||||||||||
Deferred
loan costs, net
|
(203,457 | ) | 9,750 | (7) | (193,707 | ) | |||||||
Net
cash provided by financing activities
|
1,381,338 | 15,693 | 1,397,031 | ||||||||||
Effect
of exchange rates on cash and equivalents
|
(8,988 | ) | - | (8,988 | ) | ||||||||
Increase
in cash and cash equivalents
|
218,099 | - | 218,099 | ||||||||||
Cash
and cash equivalents at beginning of year
|
50,899 | - | 50,899 | ||||||||||
Cash
and cash equivalents at end of year
|
$ | 268,998 | $ | - | $ | 268,998 | |||||||
Supplemental
disclosures of cash flow information:
|
|||||||||||||
Cash
paid during the year for:
|
|||||||||||||
Interest
|
$ | 157,599 | $ | - | $ | 157,599 | |||||||
Income
taxes
|
- | - | |||||||||||
See
accompanying notes to consolidated financial statements
|
(1) Net loss decreased due to
changes reflected in the restated consolidated statement of operations
above.
|
(2)
Minority interest in loss of subsidiaries change due to restated financial
statements based on ownership percentage held by minority
shareholders.
|
(3)
Prepaid expenses and other current assets change due to prepaid insurance
of $31,079 and prepaid payroll of $30,310.
|
(4)
Accounts payable and accrued expenses change due to Wilbur Street rent
accrual increase of $78,854 and payroll tax liability accrual of $35,000
for our Curacao employees.
|
(5) Net
paydown of notes receivable from former Chairman and CEO change due to the
improper treatment of prior period payments.
|
(6)
Interest accrued on notes payable to a related party and a former
director.
|
(7) Deferred loan costs, net
change due to a decrease in loan amortization of $9,750 of Bio Partners, a
private investor group.
|
Twelve
month period
|
||||||||||||
2003
|
2004
|
2005
|
||||||||||
Beginning
balance product warranty liability
|
$ | 318,342 | $ | 178,342 | $ | 165,824 | ||||||
Change
in liability
|
(140,000 | ) | (12,518 | ) | (67,965 | ) | ||||||
Ending
balance of product warranty liability
|
$ | 178,342 | $ | 165,824 | $ | 97,859 |
December 31, 2005
|
December 31, 2004
|
December 31, 2003
|
||||||||||
Year
Ended
|
||||||||||||
Net
loss as reported
|
$ | (1,296,746 | ) | $ | (3,658,741 | ) | $ | (3,199,543 | ) | |||
Deduct:
Total stock-based employee compensation expenses
determined
under fair value based method for all awards, net effect of minority interest |
(105,587 | ) | (236,573 | ) | (221,361 | ) | ||||||
Pro
forma net loss
|
$ | (1,402,333 | ) | $ | (3,895,314 | ) | $ | (3,420,904 | ) | |||
Basic
and diluted net loss per share:
|
||||||||||||
As
reported
|
||||||||||||
Basic
and diluted
|
$ | (0.26 | ) | $ | (0.75 | ) | $ | (0.68 | ) | |||
Pro
forma
|
||||||||||||
Basic
and diluted
|
$ | (0.28 | ) | $ | (0.79 | ) | $ | (0.72 | ) |
Year
Ended
|
December 31,
2005
|
December 31,
2004
|
December 31,
2003
|
Average
risk free interest rates
|
6.00%
|
4.51%
|
4.75%
|
Average
expected life (in years)
|
5.00
|
5.00
|
5.00
|
Volatility
|
87%
|
82%
|
82%
|
December
31,
|
||||||||||||
(In
thousands)
|
2005
|
2004
|
2003
|
|||||||||
Stock
options
|
963,887 | 1,055,440 | 1,350,625 | |||||||||
Convertible
Note
|
-- | 456,750 | 456,750 | |||||||||
Warrants
|
10,000 | 10,000 | 10,000 | |||||||||
Total
|
973,887 | 1,522,190 | 1,817,375 | |||||||||
December
31,
|
||||||||||||
2005
|
2004
|
2003
|
||||||||||
Raw
materials
|
$ | 84,087 | $ | 109,671 | $ | 65,166 | ||||||
Work-in-process
|
2,532,629 | 2,028,732 | 815,286 | |||||||||
Reserved
for recall
|
-- | (133,140 | ) | -- | ||||||||
$ | 2,616,716 | $ | 2,005,263 | $ | 880,452 |
December
31,
|
||||||||||||
2005
|
2004
|
2003
|
||||||||||
Machinery
and equipment
|
$ | 2,478,966 | $ | 2,530,068 | $ | 2,379,796 | ||||||
Furniture
and fixtures
|
173,339 | 381,588 | 371,917 | |||||||||
Leasehold
improvements
|
4,139,235 | 4,114,595 | 4,079,120 | |||||||||
6,791,540 | 7,026,251 | 6,830,833 | ||||||||||
Less
accumulated depreciation and amortization
|
(3,996,185 | ) | (3,630,860 | ) | (2,985,730 | ) | ||||||
$ | 2,795,355 | $ | 3,395,391 | $ | 3,845,103 |
December
31,
|
||||||||||||
2005
|
2004
|
2003
|
||||||||||
Trade
accounts payable and accrued expenses
|
$ | 1,898,002 | $ | 1,184,401 | $ | 1,191,471 | ||||||
Accrued
legal and other professional fees
|
124,984 | 940,545 | 542,036 | |||||||||
Accrued
payroll and related costs
|
615,846 | 369,221 | 315,305 | |||||||||
$ | 2,638,832 | $ | 2,494,168 | $ | 2,048,812 | |||||||
Year
ended
|
December
31,
|
|||||||||||
2005
|
2004
|
2003
|
||||||||||
Current:
|
||||||||||||
Federal
|
$ | -- | $ | -- | $ | 13,000 | ||||||
State
|
6,118 | -- | -- | |||||||||
$ | 6,118 | $ | -- | $ | 13,000 | |||||||
Deferred:
|
||||||||||||
Federal
|
-- | -- | -- | |||||||||
State
|
-- | -- | -- | |||||||||
Total
|
$ | 6,118 | $ | -- | $ | 13,000 | ||||||
Year
ended
|
December
31,
|
|||||||||||
2005
|
2004
|
2003
|
||||||||||
Computed
tax benefit at statutory rate
|
$ | 453,861 | $ | 1,307,863 | $ | 1,031,677 | ||||||
Tax
effect of foreign sourced income (loss)
|
(150,495 | ) | 163,923 | (397,422 | ) | |||||||
State
income taxes, net of federal tax benefit
|
(3,971 | ) | -- | -- | ||||||||
Non-deductible
expenses
|
(9,191 | ) | (13,909 | ) | (4,116 | ) | ||||||
Orphan
drug and other tax credits
|
554,498 | 99,038 | 25,394 | |||||||||
Increase
in valuation allowance
|
(844,702 | ) | (1,556,914 | ) | (642,533 | ) | ||||||
$ | - | $ | - | $ | (13,000 | ) |
December
31,
|
||||||||||||
2005
|
2004
|
2003
|
||||||||||
Tax
Credit carryforward
|
$ | 2,119,864 | $ | 1,158,125 | $ | 1,059,087 | ||||||
Inventory
|
37,007 | 87,452 | 34,226 | |||||||||
Accrued
expenses
|
68,727 | 68,726 | 61,918 | |||||||||
Depreciation
and amortization
|
17,170 | 58,383 | 49,351 | |||||||||
Capital
loss carryforward
|
68,178 | 68,178 | 66,412 |
Net
operating loss carryforward
|
2,320,640 | 2,252,554 | 870,465 | |||||||||
Net
deferred tax assets before valuation allowance
|
4,631,586 | 3,693,418 | 2,141,458 | |||||||||
Valuation
allowance
|
(4,631,586 | ) | (3,693,418 | ) | (2,141,458 | ) | ||||||
Net
deferred tax asset
|
$ | - | $ | - | $ | - |
December
31,
|
||||||||||||||||||||||||
2005
|
2004
|
2003
|
||||||||||||||||||||||
Shares
|
Weighted
Average Exercise Price
|
Shares
|
Weighted
Average Exercise Price
|
Shares
|
Weighted
Average Exercise Price
|
|||||||||||||||||||
Outstanding
at beginning of year
|
1,056,358 | $ | 1.63 | 1,350,625 | $ | 1.77 | 1,358,325 | $ | 1.98 | |||||||||||||||
Options
granted
|
37,054 | 1.44 | 80,958 | 1.56 | 50,000 | 1.28 | ||||||||||||||||||
Options
exercised
|
(13,875 | ) | 1.00 | (65,425 | ) | 1.00 | -- | -- | ||||||||||||||||
Options
canceled or expired
|
(115,650 | ) | 2.36 | (309,800 | ) | 4.62 | (57,700 | ) | 2.77 | |||||||||||||||
Outstanding
at end of year
|
963,887 | $ | 1.63 | 1,056,358 | $ | 1.63 | 1,350,625 | $ | 1.77 | |||||||||||||||
Options
exercisable at year end
|
918,887 | $ | 1.44 | 920,913 | $ | 1.67 | 1,250,625 | 1.86 | ||||||||||||||||
Shares
available for future grant
|
1,242,263 | -- | 1,226,200 | -- | 1,006,150 | -- |
Outstanding
|
Exercisable
|
|||||||||||||||||||||
Option
Exercise Price
|
Shares
|
Weighted
Average Life (years)
|
Weighted
Average Exercise Price
|
Shares
|
Weighted
Average Option
Price
|
|||||||||||||||||
$ | 0.80-1.49 | 693,604 | 6.08 | $ | 1.01 | 684,224 | $ | 1.01 | ||||||||||||||
1.50-1.99 | 180,737 | 6.81 | 1.69 | 144,355 | 1.72 | |||||||||||||||||
2.00-2.99 | 35,671 | 4.60 | 2.65 | 35,583 | 2.65 | |||||||||||||||||
3.00-3.99 | 27,500 | 2.83 | 3.23 | 27,500 | 3.23 | |||||||||||||||||
4.00-4.99 | 23,875 | 2.36 | 4.29 | 23,875 | 4.29 | |||||||||||||||||
5.00-6.05 | 2,500 | 2.33 | $ | 5.81 | 2,500 | $ | 5.81 | |||||||||||||||
963,887 | 5.88 | $ | 1.45 | 938,038 | $ | 1.44 |
|
2006
|
$160,000
|
|
2007
|
154,000
|
|
2008
|
154,000
|
|
2009
|
153,000
|
|
2010
|
75,000
|
Exhibit
Number |
Description
|
23
|
|
31
|
|
32
|
BIOSPECIFICS
TECHNOLOGIES CORP.
|
||
By: | /s/ Thomas L. Wegman | |
Thomas
L. Wegman
President, Principal Executive Officer and Principal Financial Officer |